ok yes many trials are unique but in the end have the same goal (breast cancer detection trials)to detect breast cancer early .
BREAST CANCER STUDY The STRIVE Study is designed to test a new option for breast cancer screening. Using technology developed by GRAIL Inc. (Menlo Park, California), the STRIVE Study will gather blood samples from 120,000 women at the time of their screening mammogram. These samples will be tested for small pieces of DNA and RNA released into the blood by tumors.
This study will look at whether a blood test can:
Find the breast cancers that mammograms find Find the breast cancers that mammograms miss Reduce the number of times women without cancer need follow-up to rule out cancer Increase the chances that a breast biopsy is recommended only for the very few who have cancer The earlier that breast cancer can be found, the greater the chance of a cure. The goal of the STRIVE Study is to make this blood test available to women in the next five years.
one trial will aim to get 120000 in less than 5 years while the other cant get less than 100 in the same amount of time, has lied to holders, barely release any info , has done questionable deals... I see a pattern here and if it continues it wont end well for llbo holders. TBH I really don't care if you think the trial above is completely different ,I'm not wasting my energy defending anything my post wasn't indented to get anyone to sell , so off course you'll hold really what choice do you have - its all or nothing at this point.
example of the lies- LLBO's primary asset is its investment in Cyrcadia Inc. (Cyrcadia). That investment is achieving meaningful added value as Cyrcadia prepares to enter the final clinical trials that will be conducted at El Camino Hospital (ECH) in Mountain View, CA and the Ohio State University (OSU) Oncology Hospital in Columbus, OH. The trials have been approved through Investigational Review Boards (IRB's) of ECH and are currently undergoing the review process at OSU. The ECH trial is slated for start before the end of April 2015. The trials are expected to be completed in four to 6 months. On completion Cyrcadia will obtain CE Marking allowing for sales and marketing outside of the USA. On completion of the trials Cyrcadia will be submitting a 510(k) to the FDA. Post clearance, marketing will begin in the USA. International sales are expected in Q4 of 2015 and US sales in Q1 or Q2 of 2016.
News 
Market Data 
Discover 
